Human monoclonal antibodies against CD25

Details Human monoclonal antibodies against CD25 Human monoclonal antibodies against CD25

2003-11-14

2008-10-21

Blanchard, David J. (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S144100, C530S388220

Reexamination Certificate

active

07438907

ABSTRACT:
Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

REFERENCES:
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4816565 (1989-03-01), Honjo et al.
patent: 4845198 (1989-07-01), Urdal et al.
patent: 5011684 (1991-04-01), Strom
patent: 5152980 (1992-10-01), Strom et al.
patent: 5317087 (1994-05-01), Cerretti et al.
patent: 5326559 (1994-07-01), Miller
patent: 5336489 (1994-08-01), Strom
patent: 5356795 (1994-10-01), Leonard et al.
patent: 5510105 (1996-04-01), Strom
patent: 5530101 (1996-06-01), Queen et al.
patent: 5587162 (1996-12-01), Strom
patent: 5607675 (1997-03-01), Strom
patent: 5674494 (1997-10-01), Strom
patent: 5916559 (1999-06-01), Strom
patent: 6074636 (2000-06-01), Nichols
patent: 6113900 (2000-09-01), Strom
patent: 6383487 (2002-05-01), Amlot et al.
patent: 2001/0041179 (2001-11-01), Feutren et al.
patent: 2002/0012962 (2002-01-01), Stahl et al.
patent: 272471 (1989-10-01), None
patent: 421876 (1990-10-01), None
patent: 296082 (1994-04-01), None
patent: 548194 (1995-05-01), None
patent: 380542 (1996-04-01), None
patent: 510949 (2003-04-01), None
patent: WO 88/09671 (1988-12-01), None
patent: WO 89/01340 (1989-02-01), None
patent: WO 89/11287 (1989-11-01), None
patent: WO 91/00921 (1991-01-01), None
patent: WO 92/03918 (1992-03-01), None
patent: WO 92/04051 (1992-03-01), None
patent: WO 92/13886 (1992-08-01), None
patent: WO 92/15318 (1992-09-01), None
patent: WO 92/20364 (1992-11-01), None
patent: WO 92/20701 (1992-11-01), None
patent: WO 94/25585 (1994-11-01), None
patent: WO 98/24884 (1998-06-01), None
patent: WO 99/36437 (1999-07-01), None
patent: WO 99/43798 (1999-09-01), None
patent: WO 00/18932 (2000-04-01), None
patent: WO 00/25816 (2000-05-01), None
patent: WO 00/30679 (2000-06-01), None
patent: WO 00/71159 (2000-11-01), None
patent: WO 02/07783 (2002-01-01), None
patent: WO 02/07783 (2002-01-01), None
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.
Schwartz et al, Proc Natl Acad Sci USA vol. 84:6408-6411 (1987).
Lin et al Biochemistry USA vol. 14:1559-1563 (1975).
Rudikoff et al. (Proc. Natl. Acad. Sci USA 1982 79:1979) 1983.
Green (J. Immunol. Methods 231:11-23 (1999).
Osterberg et al. (Biochemical Society Transactions 23:1038-1043 (1995).
Henry et al. (Expert Opin. Pharmacother. 3(11):1657-1663 (2002).
Pascual et al. Nephrol Dial Transplant 16:1756-1760 (2001).
Davis et al. (1999) Can. Metastasis Rev. 18:421-425.
Gallo et al. Eur. J. Immunol. (2000) 30:534-540.
MacCallum et al. (1996) J. Mol. Biol. 262:732-745.
Pascalis et al. (2002) The Journal of Immunology 169:3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Holm et al (2007) Mol. Immunol. 44: 1075-1084.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Jang et al. (1998) Molec. Immunol. 35:1207-1217.
Brorson et al. (1999) J. Immunol. 163:6694-6701.
Coleman (1994) Research in Immunol. 145:33-36.
Vajdos et al. (2002) J. Mol. Biol. 320, 415-428.
Preston et al. (Infect. Immun. 66(9):4137-4142 (1998)).
Yarnold and Fell (Can. Res. 54:506-512 (1994)).
Morrison et al. (PNAS 88:6851-6855 (1994)).
Boel et al. (J. Immunol. Methods 239:153-166 (2000)).
Leonard et al. “Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.”Nature. Oct. 18-24, 1984;311(5987):626-31.
Nikaido et al. “Molecular cloning of cDNA encoding human interleukin-2 receptor.”Nature. Oct. 18-24, 1984;311(5987):631-5.
Uchiyama et al. “A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.”J Immunol. Apr. 1981;126(4):1393-7.
Jakobovits, Aya, “The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice,”Exp. Opin. Invest. Drugs., vol. 7(4):607-614.
Green, Larry L., “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies,”Journal of Immunological Methods, vol. 231:11-23 (1999).
Henry, Mitchell L. et al., “The use of basiliximab in solid organ transplantation,”Expert Opin. Pharmacother., vol. 3(10):1657-1663 (2002).
Östberg, L. et al., “Human and humanized monoclonal antibodies: preclinical studies and clinical experience,” Biochemical Society Transactions, vol. 23(4):1038-1043 (1995).
Pascual, Julio et al., “Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab,”Nephrol Dial Transplant, vol. 16:1756-1760 (2001).
Supplementary European Search Report for Application No. EP03786661, dated Mar. 23, 2007.
Baan, Carla C. et al., “Anti-CD25 Therapy Reveals the Redundancy of the Intragraft Cytokine Network After Clinical Heart Transplantation,”Transplantation, vol. 67(6):870-876 (1999).
Baan, Carla C. et al., “Functional Responses of T Cells Blocked by Anti-CD25 Antibody Therapy During Cardiac Rejection,”Transplantation, vol. 69(3):331-336 (2000).
Baan, Carla C. et al., “IL-15R α-Chain Expression During Anti-CD25 Treatment of Cardiac Allograft Recipients,”Transplantation Proceedings, vol. 34:3243-3245 (2002).
Benito, José M. et al., “Quantitative Alterations of the Functionally Distinct Subsets of CD4 and CD8 T Lymphocytes in Asymptomatic HIV Infection: Changes in the Expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 Antigens,”Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 14(2):128-135 (1997).
Engert, Andreas et al., “A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma,”Blood, vol. 89(2):403-410 (1997).
Hartmann, Frank et al., “Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody212Bi-anti-Tac,”Cancer Research, vol. 54:4362-4370 (1994).
Jakob, Thilo et al., “Stage-dependent Expression of CD7, CD45RO, CD45RA and CD25 on CD4-positive Peripheral Blood T-lymphocytes in Cutaneous T-cell Lymphoma,”Acta dermatovenereologica, vol. 76(1):34-36 (1996).
Jones, Emma et al., “Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice,”Cancer Immunity, vol. 2(1):1-12 (2002).
Kreitman, Robert J. et al., “Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies,”Journal of Clinical Oncology, vol. 18(8):1622-1636 (2000).
Krueger, James G. et al., “Sucessful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis,”J. Am. Acad. Dermatol., vol. 43:448-458 (2000).
Kupiec-Weglinski, Jerzy W., “CD25-Targeted Therapy Revisited,”Transplantation, vol. 69(3):328-330 (2000).
Laurie, Karen L. et al., “The role of CD4+CD25+ immunoregulatory T cells in the induction of autoimmune gastritis,”Immunology and Cell Biology, vol. 80:567-573 (2002).
Mrowietz, Ulrich et al., “Treatment of Severe Psoriasis With Anti-CD25 Monoclonal Antibodies,”Arch. Dermatol., vol. 136:675-676 (2000).
Onizuka, Shozaburo et al., “Tumor Rejectino by In Vi

Affiliated with

Also associated with

Rating

Human monoclonal antibodies against CD25 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human monoclonal antibodies against CD25, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human monoclonal antibodies against CD25 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3989005